NeuroScientific Biopharmaceuticals has notched a major regulatory milestone after securing approval from Australia’s Therapeutic Goods Administration (TGA) to treat patients affected with severe Crohn’s disease with its proprietorial stem cell therapy.

Stem cell therapies have long promised to press the body’s reset button - potentially reversing injuries and damage from disease, regenerating tissue and reshaping modern medicine.

NeuroScientific Biopharmaceuticals will start trialling its proprietorial stem cell therapy for the first time on patient suffering from acute Crohn’s disease.

Crohn’s disease is a painful autoimmune gut condition that can turn lives upside down. However, long-suffering patients may just be starting to see a light at the end of what has been a very long and dar

See Full Page